4Enc FY, Imerylyuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release[JJ. Am J Physiol Gastrointest Liver Physiol, 2001, 281(3) : 752-763.
6McKeage K,Goa KL.Insulin glargine:a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 dia2 betes mellitus.Drugs,2001,61 (11):1599 ～ 1624.
7Hamann A,Matthaei S,Rosak C,et al.A randomized clinical trial comparing breakfast,dinner,or bedtime administration of insulinglargine in patients with type 1 diabetes.Diabetes Care,2003,26(6):1738 ～ 1744.
8Owens DR,Coates PA,Luzio SD,et al.Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men:comparison with NPH insulin and the influence of different subcutaneous injection sites.Diabetes Care,2000,23(6):813 ～819.
9Tarin C,Teufel E,Pico J,et al.Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations.IEEE Trans Biomed Eng,2005,52 (12):1994 ～ 2005.
10Riddle MC,Rosenstock J,Gerich J.The treat to target trial:randomized addition of glargine or human NPH insulin to oral therapy oftype 2 diabetic patients.Diabetes Care,2003,6 (11):3080 ～3086.
7Fujitaka K,Otani H,Jo F,et al. Comparison of metabolic profile and adiponeetin level with pioglitazone versus voglibose in patients with type -2 diabetes mellitus associated with metabolic syndrome [ J ]. Endocr J,2011,58(6) :425 -432.
8Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12 - week, randomized, double-blind, active-controlled study [ J ], Diabetes Obes Metab,2010,12 ( 8 ) :700 - 708.
9Matsumura M,Monden T, Miyashita Y,et al. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 di- abetes mellitus patients [ J ]. Adv Ther, 2009,26 ( 6 ) : 660 - 666.
10Robyn J,Gabrielia T,TienY, et al. Longitudinal association of glu- cose metabolism with retinopathy[ J]. Diabetes Care,2008,31 (7) : 1349 - 1354.
